argenx (ARGX) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed argenx (ARGX) over the past year, gaining 27.2% versus a gain of 16.4%. Over five years, ARGX leads with a +216.1% price change compared with +34.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($76.40 billion vs $57.74 billion), about 1.3 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.1x vs 26.7x for argenx). Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while argenx does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | REGN |
|---|---|---|
| Share price | $928.44 | $742.12 |
| Market cap | $57.74B | $76.40B |
| 1-day change | -0.22% | +0.46% |
| YTD return | +10.40% | -3.85% |
| 1-year return | +16.44% | +27.24% |
| 5-year return | +216.08% | +34.14% |
| P/E ratio (TTM) | 35.38 | 18.35 |
| Forward P/E | 26.74 | 12.07 |
| EPS (TTM) | $26.24 | $40.44 |
| Dividend yield | 0.00% | 0.49% |
| Annual dividend | $0.00 | $3.64 |
| Revenue (latest FY) | — | $14.34B |
| Revenue growth (YoY) | — | +0.99% |
| Net income (latest FY) | $1.29B | $4.50B |
| Operating margin | — | 24.95% |
| Net margin | — | 31.41% |
| 52-week high | $1,072.75 | $859.34 |
| 52-week low | $661.85 | $541.00 |
| Distance from 52-week high | -13.45% | -13.64% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +27.12% | +15.38% |
| Average volume | 283.80K | 741.47K |
| Shares outstanding | 62.19M | 101.14M |
| Employees | 1,863 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REGN has outperformed ARGX by 10.8 percentage points over the past year.
- argenx trades at a higher earnings multiple (35.4x vs 18.4x trailing P/E).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
ARGX vs REGN FAQ
Which is bigger, argenx or Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $76.40B compared with $57.74B for argenx (ARGX).
Which stock has performed better over the past year, ARGX or REGN?
REGN returned +27.24% over the past 12 months, compared with +16.44% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or REGN?
REGN has the lower trailing P/E at 18.4, versus 35.4 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, argenx or Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while argenx does not currently pay a regular dividend.
Are argenx and Regeneron Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Pharmaceutical Preparations for Regeneron Pharmaceuticals.